Cited by 15,011Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifeVoice and Speech Disorders

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, John F.·1983·Neurology

DOI 10.1212/wnl.33.11.1444

Open this paper in CoChat — free account

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Integrity signals

Registry

Crossref · 10.1212/wnl.33.11.1444

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps.
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
THE SOCIO-ECONOMIC SCALE
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20

Show all 13 references

Sorted by citations

Items 201–300 of 1,135

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & on behalf of the MSF204 Investigators (2010) · Annals of Neurology · doi:10.1002/ana.22240 · Cited by 373
Progression of regional grey matter atrophy in multiple sclerosis
Eshaghi, A., Marinescu, R. V., Young, A. L., Firth, N. C., Prados, F., Cardoso, M. J., Tur, C., Angelis, F. D., Cawley, N., Brownlee, W. J., et al. (2018) · Brain · doi:10.1093/brain/awy088 · Cited by 367
The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody
Höftberger, R., Guo, Y. X., Flanagan, E. P., Lopez-Chiriboga, A. S., Endmayr, V., Hochmeister, S., Joldic, D., Pittock, S. J., Tillema, J. M., Gorman, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02132-y · Cited by 379
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.
Filippi, M., Bozzali, M., Rovaris, M., Gonen, O., Kesavadas, C., Ghezzi, A., Martinelli, V., Grossman, R., Scotti, G., Comi, G., et al. (2003) · Brain : a journal of neurology · doi:10.1093/brain/awg038 · Cited by 384
A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency
Zamboni, P., Galeotti, R., Menegatti, E., Malagoni, A. M., Gianesini, S., Bartolomei, I., Mascoli, F., & Salvi, F. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.07.096 · Cited by 371
Regional DTI differences in multiple sclerosis patients
Roosendaal, S. D., Geurts, J. J. G., Vrenken, H., Hulst, H. E., Cover, K. S., Castelijns, J. A., Pouwels, P. J. W., & Barkhof, F. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.026 · Cited by 378
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
Rudick, R. A., Antel, J. P., Confavreux, C., Cutter, G., Ellison, G. W., Fischer, J. S., LUBLIN, F. D., Miller, A., Petkau, J., Rao, S. M., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420318 · Cited by 370
Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500508 · Cited by 371
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H., Miller, D. H., Montalbán, X., Barkhof, F., Radue, E. W., Metzig, C., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70237-6 · Cited by 374
Water content and myelin water fraction in multiple sclerosis
Laule, C., Vavasour, I. M., Moore, G. R. W., Oger, J. J.-F., Li, D. K. B., Paty, D. W., & MacKay, A. L. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0306-6 · Cited by 369
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
Harding, K. E., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T. P., Robertson, N. P., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 377
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.
Miller, D. H., Barkhof, F., Berry, I., Kappos, L., Scotti, G., & Thompson, A. J. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.8.683 · Cited by 368
Prediction of Neuropsychological Impairment in Multiple Sclerosis
Benedict, R. H. B., Weinstock‐Guttman, B., Fishman, I., Sharma, J., Tjoa, C. W., & Bakshi, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.226 · Cited by 369
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Comı, G., Jeffery, D., Kappos, L., Montalbán, X., Boyко, A., Rocca, M. A., & Filippi, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1104318 · Cited by 364
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt, G. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.090365 · Cited by 370
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
Burton, J. M., Kimball, S., Vieth, R., Bar‐Or, A., Dosch, H. M., Cheung, R., Gagne, D., D'Souza, C., Ursell, M. R., & O'Connor, P. W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cec2 · Cited by 360
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
O'Connor, P. W., Li, D., Freedman, M. S., Bar‐Or, A., Rice, G. P., Confavreux, C., Paty, D. W., Stewart, J. A., & Scheyer, R. D. (2006) · Neurology · doi:10.1212/01.wnl.0000203121.04509.31 · Cited by 357
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Vermersch, P., Członkowska, A., Grimaldi, L. M., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Bénamor, M., Bauer, D., Truffinet, P., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513507821 · Cited by 353
Central pain in multiple sclerosis — prevalence and clinical characteristics
Österberg, A., Boivie, J., & Thuomas, K. (2005) · European Journal of Pain · doi:10.1016/j.ejpain.2004.11.005 · Cited by 345
Diagnostic criteria for primary progressive multiple sclerosis: a position paper.
Thompson, A. J., Montalbán, X., Barkhof, F., Brochet, B., Filippi, M., Miller, D. H., Polman, C. H., Stevenson, V. L., & McDonald, W. I. (2000) · PubMed · Cited by 352
Predicting accidental falls in people with multiple sclerosis — a longitudinal study
Nilsagård, Y. E., Lundholm, C., Denison, E., & Gunnarsson, L. (2009) · Clinical Rehabilitation · doi:10.1177/0269215508095087 · Cited by 349
Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
Kalra, S., Silman, A. J., Akman‐Demir, G., Bohlega, S., Borhani‐Haghighi, A., Constantinescu, C. S., Houman, H., Mahr, A., Salvarani, C., Sfikakis, P. P., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7209-3 · Cited by 348
Gray matter involvement in multiple sclerosis
Pirko, I., Lucchinetti, C. F., Sriram, S., & Bakshi, R. (2007) · Neurology · doi:10.1212/01.wnl.0000250267.85698.7a · Cited by 355
A review about the impact of multiple sclerosis on health-related quality of life
Benito‐León, J., Morales, J. M., Navarro, J. R., & Mitchell, A. J. (2003) · Disability and Rehabilitation · doi:10.1080/09638280310001608591 · Cited by 366
Meaning in life and physical health: systematic review and meta-analysis
Czekierda, K., Banik, A., Park, C. L., & Łuszczyńska, A. (2017) · Health Psychology Review · doi:10.1080/17437199.2017.1327325 · Cited by 382
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis
Ramanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384
Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study
Reindl, M., Linington, C., Brehm, U., Egg, R., Dilitz, E., Deisenhammer, F., Poewe, W. H., & Berger, T. (1999) · Brain · doi:10.1093/brain/122.11.2047 · Cited by 347
Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
McFarland, H. F., Frank, J. A., Albert, P. S., Smith, M. E., Martinꝉ, R., Harris, J. O., Patronas, N. J., Maloni, H. W., & McFarlin, D. E. (1992) · Annals of Neurology · doi:10.1002/ana.410320609 · Cited by 347
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Zivadinov, R., Rudick, R. A., Masi, R. D., Nasuelli, D., Ukmar, M., Pozzi–Mucelli, R. S., Grop, A., Cazzato, G., & Zorzon, M. (2001) · Neurology · doi:10.1212/wnl.57.7.1239 · Cited by 341
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Gunnarsson, M., Malmeström, C., Axelsson, M., Sundström, P., Dahle, C., Vrethem, M., Olsson, T. P., Piehl, F., Norgren, N., Rosengren, L., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22247 · Cited by 346
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?
Heesen, C. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065805 · Cited by 343
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study
Banwell, B., Krupp, L., Kennedy, J., Tellier, R., Tenembaum, S. N., Ness, J., Belman, A. L., Boiko, A., Быкова, О. В., Waubant, E. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70196-5 · Cited by 344
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12271 · Cited by 360
Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I
Clarke, L. A., Wraith, J. E., Beck, M., Kolodny, E. H., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Sidman, M., Kakkis, E., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2007-3847 · Cited by 343
Correlation of magnetization transfer ration with clinical disability in multiple sclerosis
Gass, A., Barker, G. J., Kidd, D. P., Thorpe, J. W., MacManus, D. G., Brennan, A., Tofts, P. S., Thompson, A. J., McDonald, W. I., & Miller, D. H. (1994) · Annals of Neurology · doi:10.1002/ana.410360113 · Cited by 343
Course and prognosis in early-onset MS
Simone, I. L., Carrara, D., Tortorella, C., Liguori, M., Lepore, V. L., Pellegrini, F., Bellacosa, A., Ceccarelli, A., Pavone, I., & Livrea, P. (2002) · Neurology · doi:10.1212/01.wnl.0000036907.37650.8e · Cited by 341
The pathophysiology of multiple sclerosis⋮ the mechanisms underlying the production of symptoms and the natural history of the disease
Smith, K. J., & McDonald, W. I. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0510 · Cited by 340
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, E. P., Cabre, P., Weinshenker, B. G., Sauver, J. L. S., Jacobson, D. J., Majed, M., Lennon, V. A., Lucchinetti, C. F., McKeon, A. B., Matiello, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24617 · Cited by 338
Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis
Ishizu, T., Osoegawa, M., Mei, F.-J., Kikuchi, H., Tanaka, M., Takakura, Y., Minohara, M., Murai, H., Mihara, F., Taniwaki, T., et al. (2005) · Brain · doi:10.1093/brain/awh453 · Cited by 335
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
Ruano, L., Portaccio, E., Goretti, B., Niccolai, C., Severo, M., Patti, F., Cilia, S., Gallo, P., Grossi, P., Ghezzi, A., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516674367 · Cited by 331
Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis.
Mohr, D. C., Boudewyn, A. C., Goodkin, D. E., Bostrom, A., & Epstein, L. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.6.942 · Cited by 334
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography
Saidha, S., Syc‐Mazurek, S. B., Ibrahim, M., Eckstein, C. P., Warner, C. V., Farrell, S. K., Oakley, J. D., Durbin, M. K., Meyer, S. A., Balcer, L. J., et al. (2011) · Brain · doi:10.1093/brain/awq346 · Cited by 334
Recent developments in the assessment of quality of life in Multiple Sclerosis (MS)
Fischer, J. S., LaRocca, N. G., Miller, D. M., Ritvo, P. G., Andrews, H., & Paty, D. W. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500410 · Cited by 343
Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., & Poser, S. (1995) · Annals of Neurology · doi:10.1002/ana.410370115 · Cited by 334
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Chitnis, T., Arnold, D. L., Banwell, B., Brück, W., Ghezzi, A., Giovannoni, G., Greenberg, B. M., Krupp, L., Rostasy, K. M., Tardieu, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800149 · Cited by 333
Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course
Kalb, R. C., Brown, T. R., Coote, S. B., Costello, K., Dalgas, U., Garmon, E., Giesser, B. S., Halper, J., Karpatkin, H., Keller, J. L., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520915629 · Cited by 333
Statistics to tell the truth, the whole truth, and nothing but the truth Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers
Zakzanis, K. K. (2001) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/16.7.653 · Cited by 346
Microcystic macular oedema in multiple sclerosis is associated with disease severity
Gelfand, J. M., Nolan, R. C., Schwartz, D. M., Graves, J. S., & Green, A. J. (2012) · Brain · doi:10.1093/brain/aws098 · Cited by 332
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
Miller, D. H., Soon, D. T. L., Fernando, K., MacManus, D. G., Barker, G. J., Yousry, T. A., Fisher, E., O'Connor, P. W., Phillips, J. T., Polman, C. H., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260064.77700.fd · Cited by 332
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
Martínez‐Lapiscina, E. H., Arnow, S., Wilson, J. A., Saidha, S., Preiningerova, J. L., Oberwahrenbrock, T., Brandt, A. U., Pablo, L. E., Guerrieri, S., González‐Suarez, I., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00068-5 · Cited by 334
Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task
Staffen, W., Mair, A., Zauner, H., Unterrainer, J. M., Niederhofer, H., Kutzelnigg, A., Ritter, S., Golaszewski, S., Iglseder, B., & Ladurner, G. (2002) · Brain · doi:10.1093/brain/awf125 · Cited by 338
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study
Swanton, J. K., Rovira, À., Tintoré, M., Altmann, D. R., Barkhof, F., Filippi, M., Huerga, E. C., Miszkiel, K., Plant, G. T., Polman, C. H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70176-x · Cited by 330
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
Hobart, J. (2000) · Brain · doi:10.1093/brain/123.5.1027 · Cited by 330
Cortical lesion load associates with progression of disability in multiple sclerosis.
Calabrese, M., Poretto, V., Favaretto, A., Alessio, S., Bernardi, V., Romualdi, C., Rinaldi, F., Perini, P., & Gallo, P. (2012) · Brain : a journal of neurology · doi:10.1093/brain/aws246 · Cited by 341
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C. P., Hawkey, C. J., Labopin, M., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 327
An examination of suicidal intent in patients with multiple sclerosis
Feinstein, A. (2002) · Neurology · doi:10.1212/wnl.59.5.674 · Cited by 326
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI study
Werring, D. J. (2000) · Brain · doi:10.1093/brain/123.8.1667 · Cited by 323
Cladribine and progressive MS
Rice, G. P., Filippi, M., & Comi, G. (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 322
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Atkins, H. L., Bowman, M. A., Allan, D., Anstee, G., Arnold, D. L., Bar‐Or, A., Bence‐Bruckler, I., Birch, P., Bredeson, C., Chen, J. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30169-6 · Cited by 325
Default-mode network dysfunction and cognitive impairment in progressive MS
Rocca, M. A., Valsasina, P., Absinta, M., Riccitelli, G. C., Rodegher, M., Misci, P., Rossi, P., Falini, A., Comi, G., & Filippi, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d9ed91 · Cited by 328
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
Zhou, X., Baumann, R., Gao, X., Mendoza, M., Singh, S., Sand, I. K., Xia, Z., Cox, L. M., Chitnis, T., Yoon, H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.08.021 · Cited by 326
CNS aquaporin-4 autoimmunity in children
McKeon, A. B., Lennon, V. A., Lotze, T. E., Tenenbaum, S., Ness, J., Rensel, M. R., Kuntz, N. L., Fryer, J. P., Homburger, H. A., Hunter, J. V., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000314832.24682.c6 · Cited by 322
Spinal cord abnormalities in recently diagnosed MS patients
Bot, J., Barkhof, F., Polman, C. H., Nijeholt, G. J. L. À., de Groot, V., Bergers, E., Adèr, H. J., & Castelijns, J. A. (2004) · Neurology · doi:10.1212/wnl.62.2.226 · Cited by 320
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
Stefano, N. D., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
van der Mei, I. A. F., Ponsonby, A., Dwyer, T., Blizzard, L., Taylor, B. V., Kilpatrick, T. J., Butzkueven, H., & McMichael, A. J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0315-8 · Cited by 331
Demyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch‐Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. B. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 320
Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000158272.27070.6a · Cited by 318
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Malmeström, C., Haghighi, S., Rosengren, L., Andersen, O., & Lycke, J. (2003) · Neurology · doi:10.1212/01.wnl.0000098880.19793.b6 · Cited by 318
Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment
Amato, M. P., Bartolozzi, M. L., Zipoli, V., Portaccio, E., Mortilla, M., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., & Stefano, N. D. (2004) · Neurology · doi:10.1212/01.wnl.0000129544.79539.d5 · Cited by 316
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability
Mikaeloff, Y., Suissa, S., Vallée, L., Lubetzki, C., Ponsot, G., Confavreux, C., Tardieu, M., & KIDMUS Study Group (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2003.10.056 · Cited by 318
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis
Barcellos, L. F., Sawcer, S. J., Ramsay, P. P., Baranzini, S. E., Thomson, G. J., Briggs, F. B. S., Cree, B., Begovich, A. B., Villoslada, P., Montalbán, X., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl223 · Cited by 312
Gait analysis in multiple sclerosis: Characterization of temporal–spatial parameters using GAITRite functional ambulation system
Givon, U., Zeilig, G., & Achiron, A. (2008) · Gait & Posture · doi:10.1016/j.gaitpost.2008.07.011 · Cited by 316
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
Lycke, J., Karlsson, J.-E., Andersen, O., & Rosengren, L. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.402 · Cited by 315
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Bielekova, B., Richert, N. D., Howard, T., Blevins, G., Markovic‐Plese, S., McCartin, J., Wuerfel, J. T., Ohayon, J. M., Waldmann, T. A., McFarland, H. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402653101 · Cited by 314
Multiple sclerosis lesion quantification using fuzzy-connectedness principles
Udupa, J. K., Wei, L., Samarasekera, S., Miki, Y., van Buchem, M. A., & Grossman, R. I. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.640750 · Cited by 314
Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis
Schulz, K., Gold, S. M., Witte, J. A., Bartsch, K., Lang, U. E., Hellweg, R., Reer, R., Braumann, K.-M., & Heesen, C. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.06.009 · Cited by 313
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis
Burt, R. K., Balabanov, R. D., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., Fagius, J., ROSE, J. W., Nelson, F. M., Barreira, A. A., et al. (2019) · JAMA · doi:10.1001/jama.2018.18743 · Cited by 333
EDMUS, a European database for multiple sclerosis.
Confavreux, C., Compston, D. A. S., Hommes, O. R., McDonald, W. I., & Thompson, A. J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.8.671 · Cited by 311
Exercise and Multiple Sclerosis
White, L. J., & Dressendorfer, R. H. (2004) · Sports Medicine · doi:10.2165/00007256-200434150-00005 · Cited by 305
Multiple sclerosis in childhood: clinical features of 149 cases
Ghezzi, A., Deplano, V., Faroni, J., Grasso, M. G., Liguori, M., Marrosu, M. G., Pozzilli, C., Simone, I. L., & Zaffaroni, M. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300105 · Cited by 309
Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation
Piccio, L. M., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R. E., Fenoglio, C., Rinker, J. R., Naismith, R. T., Panina‐Bordignon, P., Passini, N., et al. (2008) · Brain · doi:10.1093/brain/awn217 · Cited by 311
Detection of Cortical Inflammatory Lesions by Double Inversion Recovery Magnetic Resonance Imaging in Patients With Multiple Sclerosis
Calabrese, M., Stefano, N. D., Atzori, M., Bernardi, V., Mattisi, I., Barachino, L., Morra, A., Rinaldi, L., Romualdi, C., Perini, P., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.10.1416 · Cited by 311
Long-term unsupervised mobility assessment in movement disorders
Warmerdam, E., Hausdorff, J. M., Atrsaei, A., Zhou, Y., Mirelman, A., Aminian, K., Espay, A. J., Hansen, C., Evers, L. J. W., Keller, A., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30397-7 · Cited by 306
The effect of anti-α4 integrin antibody on brain lesion activity in MS
Tubridy, N. J., Behan, P. O., Capildeo, R., Chaudhuri, A., Forbes, R. B., Hawkins, C. P., Hughes, R. A., Palace, J. A., Sharrack, B., Swingler, R. J., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.466 · Cited by 315
Quality of life in multiple sclerosis
Nortvedt, M. W., Riise, T., Myhr, K., & Nyland, H. (1999) · Neurology · doi:10.1212/wnl.53.5.1098 · Cited by 302
fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis
Mainero, C., Caramia, F., Pozzilli, C., Pisani, A., Pestalozza, I. F., Borriello, G., Bozzao, L., & Pantano, P. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.10.004 · Cited by 318
Assessing walking disability in multiple sclerosis
Kieseier, B. C., & Pozzilli, C. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512444498 · Cited by 307
Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis
Mohr, D. C., Goodkin, D., Likosky, W., Gatto, N. M., Baumann, K. A., & Rudick, R. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550170015009 · Cited by 306
Anti-α4 integrin therapy for multiple sclerosis
Rice, G. P., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 306
The effects of home-based resistance exercise on balance, power, and mobility in adults with multiple sclerosis
DeBolt, L. S., & McCubbin, J. A. (2004) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2003.06.003 · Cited by 306
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 304
The social impact of multiple sclerosis - a study of 305 patients and their relatives
Hakim, E. A., Bakheit, A. M. O., Bryant, T. N., Roberts, M. W. H., McIntosh‐Michaelis, S. A., Spackman, A., Martin, J. P., & McLellan, D. L. (2000) · Disability and Rehabilitation · doi:10.1080/096382800296755 · Cited by 304
Chemical pathology of acute demyelinating lesions and its correlation with disability
Stefano, N. D., Matthews, P. M., Antel, J. P., Preul, M. C., Francis, G., & Arnold, D. L. (1995) · Annals of Neurology · doi:10.1002/ana.410380610 · Cited by 304
Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
Goodkin, D. E., Rudick, R. A., MEDENDORP, S. V., Daughtry, M. M., Schwetz, K. M., Fischer, J. S., & Dyke, C. V. (1995) · Annals of Neurology · doi:10.1002/ana.410370108 · Cited by 304
Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history
Harris, J. O., Frank, J., Patronas, N., Mcfarlin, D. E., & McFarland, H. (1991) · Annals of Neurology · doi:10.1002/ana.410290515 · Cited by 334
Association between clinical disease activity and Epstein–Barr virus reactivation in MS
Wandinger, K.-P., Jabs, W. J., Siekhaus, A., Bubel, S., Trillenberg, P., Wagner, H. J., Wessel, K., Kirchner, H., & Hennig, H. (2000) · Neurology · doi:10.1212/wnl.55.2.178 · Cited by 302
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
Pröbstel, A., Dornmair, K., Bittner, R., Sperl, P., Jenne, D. E., de Magalhaes, S. L. B., Villalobos, A., Breithaupt, C., Weissert, R., Jacob, U., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c0b1 · Cited by 302
A study of tremor in multiple sclerosis
Alusi, S. H. (2001) · Brain · doi:10.1093/brain/124.4.720 · Cited by 300
Interferons in relapsing remitting multiple sclerosis: a systematic review
Filippini, G., Munari, L., Incorvaia, B., Ebers, G. C., Polman, C. H., D’Amico, R., & Rice, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12512-3 · Cited by 299

Authors: Kurtzke, J. F.
Affiliations: Georgetown University (US)
Corresponding author: Kurtzke, John F.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1983-11
Volume: 33
Issue: 11
Pages: 1444-1444
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.33.11.1444
OpenAlex: W2112165124
Cited by: 15,011
References: 13
Citations by year: 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
FWCI: 9.57
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
Keywords: multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
MeSH terms: Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks